Milrinone

CHEMBL189 Phase 4 Onaylandı Small molecule

Half-Life

—

Bioavailability

—

Protein Binding

—

Molecular Weight

211.2 g/mol

LogP

—

Phase

4

This medication strengthens heart contractions and relaxes blood vessels, helping the heart pump more effectively in acute heart failure. It is given intravenously in hospital settings and is not intended for long-term outpatient use.

Moleküler Ağırlık

211,2200 g/mol

LogP

0,00

TPSA

65,80 Å²

Lipinski RO5

Geçer

Terapötik Alanlar

Pain Management Asthma Insomnia Hypertension Chronic Pain Heart Failure

Pharmacokinetics (PK)

Pharmacodynamics (PD)

2D Yapı

SVG PNG

Cite this structure

Embed this structure

SMILES

Cc1[nH]c(=O)c(C#N)cc1-c1ccncc1

InChI

InChI=1S/C12H9N3O/c1-8-11(9-2-4-14-5-3-9)6-10(7-13)12(16)15-8/h2-6H,1H3,(H,15,16)

Molecular Formula

C12H9N3O

HBD / HBA

1 / 3

Döndürülebilir Bağlar

1

Ağır Atomlar

16

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Sıkça Sorulan Sorular

This medication strengthens heart contractions and relaxes blood vessels, helping the heart pump more effectively in acute heart failure. It is given intravenously in hospital settings and is not intended for long-term outpatient use.

Yes, Milrinone is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL189. Open-access bioactivity database.
PubChem — National Center for Biotechnology Information (NCBI). CID 4197. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.

PillFYI

Hasta dostu bilgi mi arıyorsunuz?

Milrinone PillFYI'da

Yapı

Hızlı Veriler

Formül: C12H9N3O
Eş Anlamlılar: 2

Dış Bağlantılar

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

Tıbbi Sorumluluk Reddi

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.